Catalyst Pharmaceuticals, Inc.
CPRX
$21.02
$0.150.72%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 60.53% | 242.65% | 8.03% | -21.28% | 36.80% |
| Total Depreciation and Amortization | 3.45% | 10.31% | 10.09% | 42.88% | 1,386.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -74.15% | -109.77% | 4,141.94% | 402.04% | 22.39% |
| Change in Net Operating Assets | -41.90% | 832.98% | 155.06% | 66.31% | -28.58% |
| Cash from Operations | 27.37% | 61.48% | 108.54% | 164.50% | 38.85% |
| Capital Expenditure | 99.76% | -304.69% | -- | 99.88% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 99.77% | 99.72% | -- | 99.88% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 763.49% | 1,776.42% | 229.17% | 11,122.20% | -78.35% |
| Repurchase of Common Stock | -2.43% | -- | 100.00% | 57.23% | -115.71% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -20.11% | 3.74% | -12.20% | -97.05% | -22.63% |
| Cash from Financing | 766.62% | 41.01% | 640.65% | 94,563.76% | -129.52% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 351.38% | 215.26% | 113.76% | 215.07% | -60.63% |
